WallStreetZenWallStreetZen

NASDAQ: SPRO
Spero Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their SPRO stock forecasts and price targets.

Forecast return on equity

Is SPRO forecast to generate an efficient return?

Company
N/A
Industry
355.6%
Market
208.52%

Forecast return on assets

Is SPRO forecast to generate an efficient return on assets?

Company
N/A
Industry
123.2%

SPRO earnings per share forecast

What is SPRO's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.68
Avg 2 year Forecast
-$0.69

SPRO revenue forecast

What is SPRO's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$816.0k-97.99%
Avg 2 year Forecast
$3.3M-91.95%
Avg 3 year Forecast
$33.8M-16.74%
SPRO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SPRO revenue growth forecast

How is SPRO forecast to perform vs Biotechnology companies and vs the US market?

Company
-10.48%
Industry
114.46%
Market
23.4%
SPRO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SPRO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SPRO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SPRO$2.41N/AN/A
CRBU$1.46$8.50+482.19%Strong Buy
SGMO$0.40$5.50+1,271.57%Buy
WHWK$2.91$7.00+140.55%Strong Buy
FATE$1.19$4.83+306.13%Buy
View Top Biotech Stocks

Spero Therapeutics Stock Forecast FAQ

What is SPRO's earnings growth forecast for 2026-2027?

(NASDAQ: SPRO) Spero Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.85%.

Spero Therapeutics's earnings in 2026 is -$43,836,000.On average, 3 Wall Street analysts forecast SPRO's earnings for 2026 to be $38,502,274, with the lowest SPRO earnings forecast at $36,992,381, and the highest SPRO earnings forecast at $39,634,694.

In 2027, SPRO is forecast to generate -$39,076,935 in earnings, with the lowest earnings forecast at -$37,544,506 and the highest earnings forecast at -$40,226,257.

If you're new to stock investing, here's how to buy Spero Therapeutics stock.

What is SPRO's revenue growth forecast for 2026-2028?

(NASDAQ: SPRO) Spero Therapeutics's forecast annual revenue growth rate of -10.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.4%.

Spero Therapeutics's revenue in 2026 is $40,549,000.On average, 3 Wall Street analysts forecast SPRO's revenue for 2026 to be $45,972,865, with the lowest SPRO revenue forecast at $44,170,007, and the highest SPRO revenue forecast at $47,325,008. On average, 3 Wall Street analysts forecast SPRO's revenue for 2027 to be $183,891,459, with the lowest SPRO revenue forecast at $176,680,029, and the highest SPRO revenue forecast at $189,300,031.

In 2028, SPRO is forecast to generate $1,902,127,278 in revenue, with the lowest revenue forecast at $1,827,534,051 and the highest revenue forecast at $1,958,072,198.

What is SPRO's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SPRO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 123.2%.

What is SPRO's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: SPRO) Spero Therapeutics's current Earnings Per Share (EPS) is -$0.79. On average, analysts forecast that SPRO's EPS will be $0.68 for 2026, with the lowest EPS forecast at $0.66, and the highest EPS forecast at $0.70. In 2027, SPRO's EPS is forecast to hit -$0.69 (min: -$0.67, max: -$0.71).

What is SPRO's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SPRO) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.